Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use
January 22, 2017
Share
Eyegate Pharmaceuticals, Inc. has received a patent titled enhanced delivery of a therapeutic to ocular tissues through iontophoresis. The patent covers an aqueous dexamethasone formulation comprising dexamethasone phosphate and the use of the formulation for delivering dexamethasone phosphate to ocular tissue via iontophoresis. The Company holds similar patents in the United States, Mexico, Australia and Israel, with applications pending in Europe and Brazil. EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, which is delivered into the ocular tissues though EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery System. Iontophoresis is capable of delivering substantially higher ocular drug concentrations leading to potentially greater bioavailability and therapeutic effect, therefore reducing the frequency of dosing. The EyeGate II Delivery System has the potential to offer a non-invasive method of drug delivery as an alternative to the current delivery modalities used for treating ocular diseases, such as eye drops and ocular injections. EGP-437 is being evaluated for two indications: An ongoing Phase III Pivotal Trial in anterior uveitis (indication licensed to a subsidiary of Valeant Pharmaceuticals); and a Phase II Trial, to be initiated this quarter, in post cataract surgery pain and inflammation.
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).